These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22929185)

  • 1. Specific-mutational patterns of p53 gene in bladder transitional cell carcinoma among a group of Iraqi patients exposed to war environmental hazards.
    Al-Kashwan TA; Houshmand M; Al-Janabi A; Melconian AK; Al-Abbasi D; Al-Musawi MN; Rostami M; Yasseen AA
    BMC Res Notes; 2012 Aug; 5():466. PubMed ID: 22929185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression.
    Erill N; Colomer A; Verdú M; Román R; Condom E; Hannaoui N; Banús JM; Cordon-Cardo C; Puig X
    Diagn Mol Pathol; 2004 Dec; 13(4):217-23. PubMed ID: 15538112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.
    Esrig D; Spruck CH; Nichols PW; Chaiwun B; Steven K; Groshen S; Chen SC; Skinner DG; Jones PA; Cote RJ
    Am J Pathol; 1993 Nov; 143(5):1389-97. PubMed ID: 7901994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
    Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
    J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma.
    Tiguert R; Bianco FJ; Oskanian P; Li Y; Grignon DJ; Wood DP; Pontes JE; Sarkar FH
    J Urol; 2001 Dec; 166(6):2155-60. PubMed ID: 11696726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder.
    Gao JP; Uchida T; Wang C; Jiang SX; Matsumoto K; Satoh T; Minei S; Soh S; Kameya T; Baba S
    Int J Oncol; 2000 Mar; 16(3):469-75. PubMed ID: 10675477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 codon 72 polymorphism and P53 protein expression in colorectal cancer specimens in Isfahan.
    Dastjerdi MN
    Acta Med Iran; 2011; 49(2):71-7. PubMed ID: 21598212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
    Dekairelle AF; Tombal B; Cosyns JP; Gala JL
    Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent mutations of the p53 gene and infrequent H- and K-ras mutations in urinary bladder carcinomas of NON/Shi mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine.
    Yamamoto S; Masui T; Murai T; Mori S; Oohara T; Makino S; Fukushima S; Tatematsu M
    Carcinogenesis; 1995 Oct; 16(10):2363-8. PubMed ID: 7586136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder.
    Gonzalez-Zulueta M; Shibata A; Ohneseit PF; Spruck CH; Busch C; Shamaa M; El-Baz M; Nichols PW; Gonzalgo ML; Elbaz M [corrected to El-Baz M]
    J Natl Cancer Inst; 1995 Sep; 87(18):1383-93. PubMed ID: 7658499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases.
    Zheng L; Chen H; Zhao J; Roy-Chowdhuri S; Kamat AM; Alhalabi O; Gao J; Siefker-Radtke A; Hansel DE; Czerniak B; Guo CC
    Hum Pathol; 2024 Jun; 148():1-6. PubMed ID: 38679207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer.
    Kawahara T; Kojima T; Kandori S; Kurobe M; Yoshino T; Kimura T; Nagumo Y; Ishituka R; Mitsuzuka K; Narita S; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Miyazaki J; Nishiyama H
    PLoS One; 2019; 14(8):e0220173. PubMed ID: 31369573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LOH and mutational analysis of p53 alleles in mouse urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl) nitrosamine.
    Morimura K; Yamamoto S; Murai T; Mori S; Chen TX; Wanibuchi H; Fukushima S
    Carcinogenesis; 1999 Apr; 20(4):715-8. PubMed ID: 10223204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression in transitional cell carcinoma of the urinary bladder--analysis of Tp53 gene mutations by temperature gradients and sequence in tumor tissues and in cellular urine sediments.
    Schlechte HH; Sachs MD; Lenk SV; Brenner S; Rudolph BD; Loening SA
    Cancer Detect Prev; 2000; 24(1):24-32. PubMed ID: 10757120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations.
    Hodgson A; van Rhijn BWG; Kim SS; Ding C; Saleeb R; Vesprini D; Liu SK; Yousef GM; van der Kwast TH; Xu B; Downes MR
    Pathol Res Pract; 2020 Nov; 216(11):153186. PubMed ID: 32861170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific p53 gene mutations in urinary bladder epithelium after the Chernobyl accident.
    Yamamoto S; Romanenko A; Wei M; Masuda C; Zaparin W; Vinnichenko W; Vozianov A; Lee CC; Morimura K; Wanibuchi H; Tada M; Fukushima S
    Cancer Res; 1999 Aug; 59(15):3606-9. PubMed ID: 10446970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
    Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
    Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.
    Olsson H; Hultman P; Rosell J; Söderkvist P; Jahnson S
    BMC Urol; 2013 Jan; 13():5. PubMed ID: 23356517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
    Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
    Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A hot spot for p53 mutation in transitional cell carcinoma of the bladder: clues to the etiology of bladder cancer.
    Xu X; Stower MJ; Reid IN; Garner RC; Burns PA
    Cancer Epidemiol Biomarkers Prev; 1997 Aug; 6(8):611-6. PubMed ID: 9264274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.